



BIOSENSORS
INTERNATIONAL

NEWS RELEASE

**Biosensors Acquires the Distribution Network of
Leading Indonesian Medical Distributor PT Fondaco Mitratama**

Singapore, 22 October 2007 – Biosensors International Group, Ltd. (Bloomberg: BIG SP, “Company” or “Biosensors”) announced today that it has entered into a conditional sale and purchase agreement with its distributor in Indonesia, PT Fondaco Mitratama (“Fondaco”) to acquire Fondaco’s distribution network for interventional cardiology and critical care products in Indonesia. This proposed acquisition is a strategic vertical integration process that will enable Biosensors to immediately establish a direct sales presence in one of the key growing markets in South-East Asia. Pursuant to the acquisition, the acquired business will be injected to a newly incorporated wholly-owned subsidiary of the Company, Biosensors Indonesia Pte Ltd (“Biosensors Indonesia”).

Consideration for the acquisition will be paid to Fondaco in two phases. At closing, 70% of the consideration for the acquisition will be paid through the issuance of 5.0 million new ordinary shares of Biosensors. Payment for the remaining 30% is deferred till 2010 and will be in the form of either cash or an issue of new ordinary shares, as determined in Biosensors’ sole discretion, based on Biosensors Indonesia’s performance in the fiscal year ending 31 March 2010.

Founded in 1996, Fondaco has established itself as one of the leading Indonesian distribution organizations with strong knowledge of the medical industry. Since 2001, one of Fondaco’s founding partners Mr. Rufi Susanto has been instrumental in developing the markets for the sale of interventional cardiology & critical care products. He has become a well known leader in the cardiovascular field in Indonesia over a short period of time. With this acquisition, Mr. Susanto will join Biosensors as President, Biosensors Indonesia and will be responsible for the sales and marketing of cardiovascular products in Indonesia with the objective to enhancing the growth of Biosensors’ business in Indonesia.

Noted for his entrepreneurship, Mr. Rufi Susanto commented, “I am very pleased to be part of the Biosensors’ growth strategy and success in Indonesia. When I founded Fondaco about 12 years ago, I recognized the need for high-quality medical products in Indonesia. With Biosensors’ innovative technologies, top-quality coronary products such as BioMatrix[®] drug-eluting stent can be made available to patients in Indonesia. I am confident that within the next two to three years, Biosensors can capture a very significant share of the growing Indonesian cardiovascular market.”

Mr. Chua Kee Lock, President of Biosensors said, “With a population of approximately 230 million people in Indonesia and a rapidly advancing healthcare system, the market for coronary stents is poised to grow significantly. The acquisition, combined with our recent alliance with PT Kimia Farma, one of the leading state-owned healthcare companies in Indonesia, will enable us to quickly penetrate the Indonesian market. Now with Fondaco being part of Biosensors, we have immediately established an experienced and formidable team of sales personnel necessary to capitalize on this tremendous growth opportunity.

“Based on Fondaco’s most recent sales trend, Fondaco’s interventional product business was generating annual revenue of approximately S\$4 million in Indonesia and net profit margin of around 25 percent. The revenue and profit contribution to Biosensors may vary depending on various business factors,” Mr. Chua added.

End of Release

Media & Investor Relations

Singapore

Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 62135708
Email: cm.loh@biosensors.com

United States

Allen&Caron Inc.

Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenosis drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*®, *Axxion*™, and *BioMatrix*® Freedom™, a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.